Date of Award
Ph.D. in Pharmaceutical Sciences
Moxifloxacin is available as a marketed solution (Vigamox(R) which has to be administered 3 or more times a day leading to poor patient compliance and low ocular bioavailability. The overall goal of this research was to use formulation strategies and develop patient compliant dosage forms of moxifloxacin which are sustained-release so as to improve its retention and thereby ocular bioavailability. The first strategy that was explored was to develop sustained release inserts of moxifloxacin hydrochloride using hot-melt extrusion. The inserts showed sustained release and antibacterial activity up to 24h and could potentially be a once-a-day application and improve patient compliance Another strategy that was utilized was to develop a sustained release nanoemulsion of moxifloxacin with a mucoadhesive agent (HPMC or PVP) as a non-invasive, cost-effective alternative delivery system that is known to enhance the retention and permeation of drugs. The nanoemulsions were formulated with a lower amount of surfactant as compared to the nanoemulsion which is published in the literature (Shah et al., 2019), and were found to stable at room temperature for up to 45 days. The nanoemulsion was also filtered through various 0.22-micron filters and they did not show any significant change in physicochemical properties after filtration.
Thakkar, Ruchi Amit, "SUSTAINED DELIVERY OF MOXIFLOXACIN FOR OCULAR APPLICATIONS." (2021). Electronic Theses and Dissertations. 2177.
Available for download on Saturday, February 17, 2024